Morgan Stanley
MIST icon

Morgan Stanley’s Milestone Pharmaceuticals MIST Stock Holding History

Morgan Stanley’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862K Sell
724,141
-57,734
-7% -$101K ﹤0.01% 5224
2025
Q4 		$1.58M Sell
781,875
-2,187,192
-74% -$4.71M ﹤0.01% 4953
2025
Q3 		$5.94M Buy
2,969,067
+2,148,646
+262% +$3.78M ﹤0.01% 4012
2025
Q2 		$1.59M Sell
820,421
-148,104
-15% -$197K ﹤0.01% 4854
2025
Q1 		$775K Sell
968,525
-320,616
-25% -$637K ﹤0.01% 5122
2024
Q4 		$3.04M Buy
1,289,141
+370,829
+40% +$637K ﹤0.01% 4388
2024
Q3 		$1.4M Buy
918,312
+89,658
+11% +$130K ﹤0.01% 4851
2024
Q2 		$1.09M Buy
828,654
+8,826
+1% +$14.2K ﹤0.01% 4903
2024
Q1 		$1.47M Sell
819,828
-558,972
-41% -$908K ﹤0.01% 4753
2023
Q4 		$2.3M Buy
1,378,800
+678,184
+97% +$1.84M ﹤0.01% 4845
2023
Q3 		$2.17M Sell
700,616
-104,423
-13% -$325K ﹤0.01% 4346
2023
Q2 		$2.29M Sell
805,039
-32,816
-4% -$124K ﹤0.01% 4337
2023
Q1 		$3.3M Sell
837,855
-492,333
-37% -$1.8M ﹤0.01% 4111
2022
Q4 		$5.27M Buy
1,330,188
+89,915
+7% +$473K ﹤0.01% 3719
2022
Q3 		$11.4M Sell
1,240,273
-77,900
-6% -$591K ﹤0.01% 2806
2022
Q2 		$8.11M Buy
1,318,173
+499,533
+61% +$3.07M ﹤0.01% 3288
2022
Q1 		$5.26M Sell
818,640
-7,356
-0.9% -$46K ﹤0.01% 3633
2021
Q4 		$5.41M Sell
825,996
-27,566
-3% -$165K ﹤0.01% 3638
2021
Q3 		$4.87M Sell
853,562
-31,637
-4% -$178K ﹤0.01% 3735
2021
Q2 		$4.87M Buy
885,199
+34,157
+4% +$194K ﹤0.01% 3804
2021
Q1 		$4.93M Sell
851,042
-126,699
-13% -$927K ﹤0.01% 3424
2020
Q4 		$6.55M Buy
977,741
+250,502
+34% +$1.68M ﹤0.01% 2969
2020
Q3 		$5.32M Buy
727,239
+128,850
+22% +$923K ﹤0.01% 2664
2020
Q2 		$2.26M Buy
598,389
+553,151
+1,223% +$1.78M ﹤0.01% 3484
2020
Q1 		$83K Sell
45,238
-1,533
-3% -$26.5K ﹤0.01% 5261
2019
Q4 		$749K Buy
46,771
+46,071
+6,582% +$815K ﹤0.01% 4706
2019
Q3 		$13K Hold
700
– – ﹤0.01% 6131
2019
Q2 		$19K Buy
+700
New +$14.4K ﹤0.01% 5951

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Morgan Stanley's MIST Position: Q1 2026 in Review

Morgan Stanley reduced its Milestone Pharmaceuticals (MIST) stake by 7.4% in Q1 2026, selling an estimated $101K and leaving 724,141 shares worth $862K. The position accounts for ﹤0.01% of the portfolio, ranked #5224.

Morgan Stanley first reported a position in MIST in Q2 2019 and has held it in 28 quarters since. The position peaked at $11.4M in Q3 2022. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Morgan Stanley held 724,141 shares of Milestone Pharmaceuticals worth $862K as of Q1 2026.
  • Morgan Stanley sold 57,734 Milestone Pharmaceuticals shares in Q1 2026, an estimated $101K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5224 holding.
  • Morgan Stanley first reported a position in Milestone Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Milestone Pharmaceuticals position peaked at $11.4M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.